Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Recursion Pharmaceuticals Inc's Business Segments
Recursion Pharmaceuticals Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 6
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Reportable100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 6 | 100% |
Revenue by Product & Service Category - Q1 FY2026
- License and Service97.4%
- Grant2.6%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| License and Service | $ 6 | 97.4% |
| Grant | $ 0 | 2.6% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals Inc. is a biotechnology company specializing in the use of artificial intelligence (AI) and machine learning (ML) to discover new drugs and therapeutics. The company was founded in 2013 by Dr. Chris Gibson, Dr. Blake Borgeson, and Dr. Alex Morgan, who were graduate students at the University of Utah at that time.
The main focus of Recursion Pharmaceuticals is to identify new treatments for rare diseases and other complex disorders. They leverage their advanced technology platforms to quickly and efficiently analyze large datasets, including high-resolution cellular images, genetic information, and clinical data.
One of the key technologies developed by Recursion is their proprietary platform called the Recursion Operating System (ROS). ROS combines AI and ML algorithms to process and analyze vast amounts of biological and chemical data. It can automatically recognize and classify tens of thousands of cellular images, helping researchers identify potential drug candidates.
Recursion Pharmaceuticals has also built an extensive library of cell-based disease models, which they utilize to test and validate potential drug targets. With their unique capabilities, they can rapidly evaluate thousands of compounds and predict their effects on different diseases. This accelerates the drug discovery process and increases the chances of finding effective treatments.
The company has established collaborations with academic institutions, pharmaceutical companies, and research organizations to leverage their expertise and resources. They have also formed partnerships with patient advocacy groups to gain insights into specific rare diseases and prioritize their research efforts.
In addition to their drug discovery programs, Recursion Pharmaceuticals is also actively involved in research and development projects aimed at uncovering the genetic basis of diseases. They employ techniques such as genome-wide association studies (GWAS) and CRISPR gene editing to better understand disease mechanisms and identify novel therapeutic targets.
To date, Recursion Pharmaceuticals has made significant progress in its mission to discover new drugs for rare diseases. They have built a promising pipeline of potential drug candidates that are undergoing preclinical and clinical evaluation. Some of their projects have advanced into partnership programs with major pharmaceutical companies.
Overall, Recursion Pharmaceuticals is a cutting-edge biotech company that harnesses the power of AI and ML to revolutionize the drug discovery process. With their innovative technologies and collaborative approach, they aim to bring much-needed treatments to patients suffering from rare and complex diseases.
The main focus of Recursion Pharmaceuticals is to identify new treatments for rare diseases and other complex disorders. They leverage their advanced technology platforms to quickly and efficiently analyze large datasets, including high-resolution cellular images, genetic information, and clinical data.
One of the key technologies developed by Recursion is their proprietary platform called the Recursion Operating System (ROS). ROS combines AI and ML algorithms to process and analyze vast amounts of biological and chemical data. It can automatically recognize and classify tens of thousands of cellular images, helping researchers identify potential drug candidates.
Recursion Pharmaceuticals has also built an extensive library of cell-based disease models, which they utilize to test and validate potential drug targets. With their unique capabilities, they can rapidly evaluate thousands of compounds and predict their effects on different diseases. This accelerates the drug discovery process and increases the chances of finding effective treatments.
The company has established collaborations with academic institutions, pharmaceutical companies, and research organizations to leverage their expertise and resources. They have also formed partnerships with patient advocacy groups to gain insights into specific rare diseases and prioritize their research efforts.
In addition to their drug discovery programs, Recursion Pharmaceuticals is also actively involved in research and development projects aimed at uncovering the genetic basis of diseases. They employ techniques such as genome-wide association studies (GWAS) and CRISPR gene editing to better understand disease mechanisms and identify novel therapeutic targets.
To date, Recursion Pharmaceuticals has made significant progress in its mission to discover new drugs for rare diseases. They have built a promising pipeline of potential drug candidates that are undergoing preclinical and clinical evaluation. Some of their projects have advanced into partnership programs with major pharmaceutical companies.
Overall, Recursion Pharmaceuticals is a cutting-edge biotech company that harnesses the power of AI and ML to revolutionize the drug discovery process. With their innovative technologies and collaborative approach, they aim to bring much-needed treatments to patients suffering from rare and complex diseases.
Recursion Pharmaceuticals Inc. stands at the forefront of biotechnology innovation, leveraging advanced artificial intelligence (AI) and computational biology to revolutionize drug discovery processes. Below is an extensive overview of the key segments, products, and services offered by the company:
1. AI-Enabled Drug Discovery
Recursion Pharmaceuticals employs cutting-edge AI algorithms and computational frameworks to streamline the drug discovery process. The centerpiece of their efforts is the Drug Repurposing Artificial Intelligence Platform (DRAP), which integrates deep learning techniques, computer vision, and vast biological datasets. By synthesizing data from diverse sources, the platform identifies novel drug candidates while improving upon existing compounds, honing in on those with the greatest potential to become effective therapies.
Compound Library
Recursion maintains an expansive and varied compound library, comprising numerous small molecules thoroughly assessed through high-throughput biological assays. This library supports systematic evaluation to identify promising drug candidates with specific therapeutic potential. The diversity of the library enables researchers to explore myriad chemical spaces, increasing the likelihood of discovering effective treatment options tailored to various diseases.
Disease Models
The company develops a comprehensive array of cell-based disease models that mimic a wide spectrum of human diseases. These models are generated using high-throughput screening techniques combined with gene-editing technologies such as CRISPR. They facilitate rapid identification and validation of disease mechanisms, biomarkers, and therapeutic targets, thereby accelerating the research process and enabling more efficient drug development.
Therapeutic Areas
Recursion Pharmaceuticals concentrates on a diverse range of therapeutic areas, including:
- Oncology: Developing treatments for various cancer types using insights gleaned from complex cellular interactions.
- Rare Diseases: Focusing on conditions that lack currently approved therapies, targeting the unmet needs of patients affected by these conditions.
- Immunology: Exploring immunotherapeutic approaches and drugs that enhance or modulate immune responses.
- Central Nervous System Disorders: Developing drugs targeted at neurodegenerative and psychiatric diseases, leveraging advanced model systems to study brain-related conditions.
- Infectious Diseases: Identifying drugs that can combat emerging infectious threats, utilising their capabilities to reposition existing medications for new uses.
Preclinical Development
Recursion has robust capabilities for preclinical development, which encompass comprehensive studies designed to evaluate the safety, effectiveness, and mechanisms of action of identified drug candidates. This phase includes both in vitro (test tube or culture dish) and in vivo (animal model) studies, alongside assessments of pharmacokinetics (how drugs move within the body) and toxicology (the study of adverse effects).
Partnerships and Collaborations
Recursion actively pursues partnerships and collaborations with academic institutions, pharmaceutical corporations, and other biotechnology firms. These strategic alliances are aimed at harnessing complementary expertise, diversifying resource acquisition, and gaining access to novel biological targets, which can significantly enhance their R&D capabilities and expedite project timelines.
Data Analysis and Visualization
Recognizing the importance of data in drug discovery, Recursion offers advanced data analysis and visualization tools. Their AI-driven analytics platform is designed to digest and interpret complex biological datasets generated throughout the drug discovery process. By transforming intricate data into actionable insights, these tools not only support research efforts but also facilitate the identification of new drug targets and therapeutic mechanisms.
8. Drug Repurposing
In addition to the discovery of novel compounds, Recursion specializes in drug repurposing by applying AI algorithms to uncover new therapeutic uses for existing medications. This strategic approach seeks to minimize the time and costs associated with drug development by leveraging already approved therapies, potentially accelerating their availability for new indications.
Conclusion
Together, these segments and services form a comprehensive framework through which Recursion Pharmaceuticals Inc. engages in the drug development landscape. By employing advanced computational methods and innovative experimental approaches, Recursion aims to transform the pharmaceutical industry, addressing the complexities of developing effective treatments for a broad array of challenging diseases. With a commitment to cutting-edge research and collaboration, the company positions itself as a leader in next-generation drug discovery.
1. AI-Enabled Drug Discovery
Recursion Pharmaceuticals employs cutting-edge AI algorithms and computational frameworks to streamline the drug discovery process. The centerpiece of their efforts is the Drug Repurposing Artificial Intelligence Platform (DRAP), which integrates deep learning techniques, computer vision, and vast biological datasets. By synthesizing data from diverse sources, the platform identifies novel drug candidates while improving upon existing compounds, honing in on those with the greatest potential to become effective therapies.
Compound Library
Recursion maintains an expansive and varied compound library, comprising numerous small molecules thoroughly assessed through high-throughput biological assays. This library supports systematic evaluation to identify promising drug candidates with specific therapeutic potential. The diversity of the library enables researchers to explore myriad chemical spaces, increasing the likelihood of discovering effective treatment options tailored to various diseases.
Disease Models
The company develops a comprehensive array of cell-based disease models that mimic a wide spectrum of human diseases. These models are generated using high-throughput screening techniques combined with gene-editing technologies such as CRISPR. They facilitate rapid identification and validation of disease mechanisms, biomarkers, and therapeutic targets, thereby accelerating the research process and enabling more efficient drug development.
Therapeutic Areas
Recursion Pharmaceuticals concentrates on a diverse range of therapeutic areas, including:
- Oncology: Developing treatments for various cancer types using insights gleaned from complex cellular interactions.
- Rare Diseases: Focusing on conditions that lack currently approved therapies, targeting the unmet needs of patients affected by these conditions.
- Immunology: Exploring immunotherapeutic approaches and drugs that enhance or modulate immune responses.
- Central Nervous System Disorders: Developing drugs targeted at neurodegenerative and psychiatric diseases, leveraging advanced model systems to study brain-related conditions.
- Infectious Diseases: Identifying drugs that can combat emerging infectious threats, utilising their capabilities to reposition existing medications for new uses.
Preclinical Development
Recursion has robust capabilities for preclinical development, which encompass comprehensive studies designed to evaluate the safety, effectiveness, and mechanisms of action of identified drug candidates. This phase includes both in vitro (test tube or culture dish) and in vivo (animal model) studies, alongside assessments of pharmacokinetics (how drugs move within the body) and toxicology (the study of adverse effects).
Partnerships and Collaborations
Recursion actively pursues partnerships and collaborations with academic institutions, pharmaceutical corporations, and other biotechnology firms. These strategic alliances are aimed at harnessing complementary expertise, diversifying resource acquisition, and gaining access to novel biological targets, which can significantly enhance their R&D capabilities and expedite project timelines.
Data Analysis and Visualization
Recognizing the importance of data in drug discovery, Recursion offers advanced data analysis and visualization tools. Their AI-driven analytics platform is designed to digest and interpret complex biological datasets generated throughout the drug discovery process. By transforming intricate data into actionable insights, these tools not only support research efforts but also facilitate the identification of new drug targets and therapeutic mechanisms.
8. Drug Repurposing
In addition to the discovery of novel compounds, Recursion specializes in drug repurposing by applying AI algorithms to uncover new therapeutic uses for existing medications. This strategic approach seeks to minimize the time and costs associated with drug development by leveraging already approved therapies, potentially accelerating their availability for new indications.
Conclusion
Together, these segments and services form a comprehensive framework through which Recursion Pharmaceuticals Inc. engages in the drug development landscape. By employing advanced computational methods and innovative experimental approaches, Recursion aims to transform the pharmaceutical industry, addressing the complexities of developing effective treatments for a broad array of challenging diseases. With a commitment to cutting-edge research and collaboration, the company positions itself as a leader in next-generation drug discovery.